Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease

Parkinsonism Relat Disord. 2008:14 Suppl 2:S159-64. doi: 10.1016/j.parkreldis.2008.04.022.

Abstract

Chronic L-dopa administration is associated with development of dyskinesias. The molecular mechanisms of these side-effects, however, remain elusive. Dopamine (DA) receptors interact with other receptors to form highly organized complexes where their activity is finely tuned by several proteins. The DA D1R forms a heteromeric complex with the NMDA receptor (NMDAR) and this interaction influences the trafficking of both receptors. Using the 6-hydroxydopamine rat model of Parkinson's disease, we report a correlation between the development of L-dopa-induced dyskinesias and changes in synaptic D1R/NMDAR complexes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenergic Agents / toxicity
  • Animals
  • Antiparkinson Agents / adverse effects*
  • Disease Models, Animal
  • Dyskinesia, Drug-Induced / etiology*
  • Dyskinesia, Drug-Induced / metabolism*
  • Humans
  • Levodopa / adverse effects*
  • Models, Molecular
  • Oxidopamine / toxicity
  • Parkinson Disease / drug therapy
  • Parkinson Disease / etiology
  • Protein Subunits / analysis
  • Protein Subunits / metabolism
  • Rats
  • Receptors, Dopamine / metabolism*
  • Receptors, N-Methyl-D-Aspartate / metabolism*

Substances

  • Adrenergic Agents
  • Antiparkinson Agents
  • Protein Subunits
  • Receptors, Dopamine
  • Receptors, N-Methyl-D-Aspartate
  • Levodopa
  • Oxidopamine